Frontiers in Endocrinology, Год журнала: 2024, Номер 15
Опубликована: Дек. 9, 2024
BRAFV600E mutation (BRAF
Язык: Английский
Medicina Clínica, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Medicina Clínica (English Edition), Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Процитировано
0
Salud Ciencia y Tecnología, Год журнала: 2024, Номер 4, С. 1241 - 1241
Опубликована: Июль 25, 2024
Introduction: the most prevalent endocrine cancer is thyroid (TC), which has a low death rate despite rising frequency. In order to assess clinical results of novel immunotherapeutic approaches in TC, this systematic review and meta-analysis will concentrate on treatment-related adverse events (AEs), overall response (ORR), progression-free survival (PFS), (OS). Methods: thorough search was done PubMed, Embase, ClinicalTrials.gov, covering research published between January 2018 December 2023. The inclusion criteria were satisfied by 14 research, including range TC subtypes study methodologies.Results: effectiveness immunotherapy varied throughout subtypes. advanced with PD-L1 positivity, pembrolizumab showed 9 % ORR 7-month PFS. advanced/metastatic camrelizumab + famitinib demonstrated ORRs 33,3 %-62,5 8,4-month Patients who tested positive for had greater responses spartalizumab (19 ORR) ATC. Combination treatments, such as lenvatinib, encouraging outcomes ATC poorly differentiated (PDTC), 34,3 significant increase With fixed-effects model, pooled 40,8 (95 CI, 37,2 %-44,5 %), random-effects it 33,4 20,8 %-48,9 %). Considerable heterogeneity (I2 = 94,4 %, p < 0,01) varying treatment across several protocols. Conclusion: promise tuberculosis, especially aggressive forms ATC, when used combination regimens. Subsequent investigations have refining tactics finding biomarkers patient selection
Язык: Английский
Процитировано
2
Frontiers in Endocrinology, Год журнала: 2024, Номер 15
Опубликована: Дек. 9, 2024
BRAFV600E mutation (BRAF
Язык: Английский
Процитировано
0